In a finding that could alter treatment for heart patients, those who took the anticlotting drug rivaroxaban daily after a heart attack or life-threatening chest pain had a lower risk of dying or suffering another heart attack than patients who took a placebo, according to researchers. C. Michael Gibson, HMS associate professor of medicine at Beth Israel Deaconess Medical Center and Jessica Mega, HMS assistant professor of medicine at Brigham and Women’s Hospital, are study co-authors.
